Intra-Cellular Therapies, Inc.

210 articles about Intra-Cellular Therapies, Inc.

• 

  Former Scripps and Humira Leader Richard Lerner Passes Away

  12/7/2021

  Richard Lerner, who played a significant role in shaping both Scripps Research and the San Diego life sciences ecosystem and developing AbbVie’s blockbuster drug Humira, died Dec. 2.

• Intra-Cellular Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update

  11/9/2021

  Intra-Cellular Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update

• Intra-Cellular Therapies to Host Third Quarter 2021 Financial Results Conference Call and Webcast

  11/2/2021

  Intra-Cellular Therapies, Inc. today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Tuesday, November 9, 2021, to provide a corporate update and discuss details of the Company's financial results for the quarter ended September 30, 2021.

• Intra-Cellular Therapies to Host a Virtual Event to Feature Highlights of Several of its Development Programs

  10/8/2021

  Virtual event to include discussions on our lumateperone, ITI-1284, PDE1 inhibitors and ITI-333 platforms Webcast scheduled for Wednesday, Oct. 20 from 12:30 to 3:30 p.m. ET

• 

  Clinical Catch-Up: September 27-October 1

  10/4/2021

  It was a busy week for clinical trial news. Here’s a look.

• Intra-Cellular Therapies Announces Publication of Lumateperone Pivotal Phase 3 Study in Bipolar Depression in The American Journal of Psychiatry

  9/27/2021

  Intra-Cellular Therapies, Inc. today announced the publication of the results from its lumateperone monotherapy Phase 3 clinical trial (ITI-007-404).

• 

  Intra-Cellular Bipolar Drug Shows "Significant" Benefit in Depressive Episodes

  9/27/2021

  Intra-Cellular Therapies published its Study 404 Phase III trial of lumateperone as monotherapy for major depressive episodes associated with bipolar I or bipolar II disorder. 

• Intra-Cellular Therapies to Present at the 2021 Cantor Virtual Global Healthcare Conference

  9/22/2021

  Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 2021 Cantor Virtual Global Healthcare Conference.

• Intra-Cellular Therapies Announces Publications Highlighting Beneficial Effects of Phosphodiesterase Type I Inhibition with Lenrispodun (ITI-214) on Cardiovascular Function in Patients with Heart Failure and in Models of Accelerated Aging

  9/20/2021

  Results of Study ITI-214-104 show that lenrispodun, in a Phase 1/2a Study, is well tolerated and acts as an inodilator in patients with heart failure without inducing abnormal heart rhythms

• Intra-Cellular Therapies to Present at the Canaccord Genuity 41st Annual Growth Conference

  8/10/2021

  Intra-Cellular Therapies, Inc. today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Canaccord Genuity 41st Annual Growth Conference on Thursday, August 12, 2021 at 2:30 pm PT.

• Intra-Cellular Therapies Reports Second Quarter 2021 Financial Results and Provides Corporate Update

  8/9/2021

  Intra-Cellular Therapies, Inc. today announced its financial results for the second quarter ended June 30, 2021 and provided a corporate update

• Intra-Cellular Therapies to Host Second Quarter 2021 Financial Results Conference Call and Webcast

  8/2/2021

  Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Monday, August 9, 2021, to provide a corporate update and discuss details of the Company's financial results for the quarter ended June 30, 2021.

• CAPLYTA® (lumateperone) Schizophrenia Safety and Tolerability Profile Published in the Journal, International Clinical Psychopharmacology

  6/7/2021

  Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), today announced the article, "Safety and tolerability of lumateperone: a pooled analysis of late-phase placebo-and active-controlled clinical trials” (Kane et al. 2021), was recently published online in International Clinical Psychopharmacology

• Intra-Cellular Therapies to Present at Two Upcoming Investor Conferences - May 26, 2021

  5/26/2021

  Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders, announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at two upcoming investor conferences

• Intra-Cellular Therapies Reports First Quarter 2021 Financial Results and Provides Corporate Update

  5/10/2021

  CAPLYTA supplemental new drug applications (sNDAs) for the treatment of bipolar depression in adults as both monotherapy and adjunctive treatment with lithium or valproate have been accepted for review by the FDA, with a PDUFA target action date of December 17, 2021. First quarter CAPLYTA total prescriptions (TRx) increased 23% versus the previous quarter.

• Intra-Cellular Therapies to Present at Two Upcoming Investor Conferences

  5/5/2021

  Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at two upcoming investor conferences:

• Intra-Cellular Therapies to Host First Quarter 2021 Financial Results Conference Call and Webcast

  5/4/2021

  Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders, announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Monday, May 10, 2021, to provide a corporate update and discuss details of the Company's financial results for the quarter ended March 31, 2021.

• Intra-Cellular Therapies Announces FDA Acceptance of CAPLYTA® (lumateperone) sNDAs for the Treatment of Bipolar Depression

  5/3/2021

  Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental New Drug Applications (sNDAs) for lumateperone, an investigational agent for the treatment of depressive episodes associated with bipolar I or II disorder

• Intra-Cellular Therapies Announces Investor Webcast and Presentations on Lumateperone Programs at the Upcoming American Psychiatric Association (APA) Annual Meeting

  4/22/2021

  Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, announces lumateperone presentations at the upcoming American Psychiatric Association (APA) Annual Meeting to be held May 1-3, 2021 and will hold a webcast on May 4, 2021.

• Intra-Cellular Therapies Announces Board of Director Nominations in Advance of 2021 Annual Meeting

  4/20/2021

  Board of Directors Nominates Sir Michael Rawlins GBE M.D., FRCP, FMedSci, Former Chairman of the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), as a New, Independent Director